Evaluation of the LDN-0060609 PERK Inhibitor as a Selective Treatment for Primary Open-Angle Glaucoma: An In Vitro Study on Human Retinal Astrocytes

Evaluation of the LDN-0060609 PERK Inhibitor as a Selective Treatment for Primary Open-Angle Glaucoma: An In Vitro Study on Human Retinal Astrocytes

The term glaucoma encompasses various neurodegenerative eye disorders, among which the most common is primary open-angle glaucoma (POAG). Recently, the essential role of human retinal astrocytes (HRA) in glaucoma progression has been placed in the spotlight. It has been found that placing the endopl...

Full description

Bibliographic Details
Main Authors: Wioletta Rozpędek-Kamińska, Grzegorz Galita, Kamil Saramowicz, Zuzanna Granek, Julia Barczuk, Natalia Siwecka, Dariusz Pytel, Ireneusz Majsterek
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:International Journal of Molecular Sciences
Subjects:
eIF2α
endoplasmic reticulum stress
glaucoma
glaucoma treatment
PERK
PERK inhibitor
Online Access:https://www.mdpi.com/1422-0067/25/2/728

Similar Items

Similar Items